HemaCare provides human derived biological material to China

New distribution partnership allows high-quality human primary cells to reach the Chinese market

US based HemaCare Corporation, a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, has announced a distribution agreement with Charles River’s subsidiary, Vital River, to provide the scientific community in China with direct access to healthy and disease-state human primary cells.

Beijing Vital River Laboratory Animal Technology Co., Ltd is a subsidiary of Charles River Laboratories and the premier commercial provider of research models and related services to the scientific community in China. Vital River was chosen as a partner to expand China distribution because of HemaCare’s successful and growing global relationship with Charles River Laboratories.

Under the terms of the agreement, Vital River will offer HemaCare’s full line of high-quality human primary cells and tissues to researchers in China. Vital River currently provides products to a vast number of scientists focused on benchtop research and drug discovery.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.